ArticleNature biotechnology2017
In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 231 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 3 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 3 syntheses or guidelines pooled it, 333 citations in OpenAlex.
- [Organoid-based strategies and challenges in tissue regeneration].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Pooled it
- Organoid Models of Colorectal Pathology: Do They Hold the Key to Personalized Medicine? A Systematic Review.Diseases of the colon and rectum · 2020Pooled it
- Organoids of liver diseases: From bench to bedside.World journal of gastroenterology · 2019Pooled it
- Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.Nature immunology · 2026Article
- Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1.Oncogene · 2026Article
- Tutorial: interrogating biology using organoid technologies.Nature protocols · 2026Review
- Article
- Lineage plasticity driven by GATA6 loss fuels colorectal cancer metastasis.Cell stem cell · 2026Article
- Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.Nature metabolism · 2026Article
- Colorectal cancer co-opts an epidermal wound healing program during metastasis to generate disseminated tumor cells.Nature communications · 2026Article
- Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis.bioRxiv : the preprint server for biology · 2026Article
- Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses.bioRxiv : the preprint server for biology · 2026Article
- Inducing physiological polarity and performing gene editing using CRISPR-Cas9 in human trophoblast organoids.Nature protocols · 2026Review
- Pancreatic organoids and organoid-on-a-chip platforms: from disease modeling to precision therapy.Journal of translational medicine · 2026Review
- Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modeling.Biochemistry and biophysics reports · 2026Article
- Inter-organ communication shapes human metabolic tissue states and resolves anti-diabetic drug response modes in a six-tissue microphysiological system.bioRxiv : the preprint server for biology · 2026Article
- 10-Hydroxy-2-decenoic Acid Suppresses Colorectal Cancer Progression by Inhibiting Wnt/β-Catenin Signaling and Promoting Apoptosis.Foods (Basel, Switzerland) · 2026Article
- Ubiquitination of DDX21 by HERC2 induces a dormancy-like phenotype via the NUCKS1-p21/p27 axis to promote radio-resistance in colorectal cancer cells.Cell death & disease · 2026Article
- Matrix-free cryo-microneedles array patch for 3D hair follicle organoids delivery and rapid hair regeneration.Materials today. Bio · 2026Article
- Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.Nature communications · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
34 authors at 7 institutions in 4 countries.
Jatin RoperThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.ORCID 0000-0002-8851-1352
Tuomas TammelaThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Naniye Malli CetinbasThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Adam AkkadThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Ali RoghanianThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Steffen RickeltThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Mohammad AlmeqdadiThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.ORCID 0000-0002-5503-2371
Katherine WuThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Matthias A OberliThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Francisco J Sánchez-RiveraThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Yoona K ParkThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Xu LiangThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
George EngThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Martin S TaylorDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-1560-9276
Roxana AzimiThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Dmitriy KedrinThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Rachit NeupaneThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Semir BeyazThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Ewa T SicinskaDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Yvelisse SuarezDepartment of Pathology, Tufts Medical Center, Boston, Massachusetts, USA.ORCID 0000-0002-0456-3260
James YooMolecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
Lillian ChenDepartment of Surgery, Tufts Medical Center, Boston, Massachusetts, USA.
Lawrence ZukerbergDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pekka KatajistoInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Vikram DeshpandeDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Adam J BassDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Philip N TsichlisMolecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
Jacqueline LeesThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Robert LangerThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Richard O HynesThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Jianzhu ChenThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Arjun BhutkarThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Tyler JacksThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Ömer H YilmazThe David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
Allen Institute · USMassachusetts General Hospital · USTufts Medical Center · USDana-Farber Cancer Institute · USHoward Hughes Medical Institute · USSouthampton General Hospital · GBUniversity of Helsinki · FI
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9MPilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3MUnderstanding and Improving Platinum Anticancer DrugsR01CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 1985 to 2018
$6.8MThe Extracellular Matrix in Tumor Progression and MetastasisU54CA163109 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEINBERG, ROBERT A · 2011 to 2015
$3.7MCELL-SURFACE STRUCTURE AND TRANSFORMATIONSR01CA017007 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYNES, RICHARD O · 1985 to 2005
$2.9M(PQB6)Elucidating metastasis by real-time monitoring and tagging of CTCs in GEMMsR01CA184956 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JACKS, TYLER E., MANALIS, SCOTT R · 2014 to 2017
$2.4MControl of V(D)J Recombination at the TCR beta LocusR01AI040146 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CHEN, JIANZHU · 1997 to 2007
$2.1MDietary control of stem cells in physiology and cancerR01CA211184 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2017 to 2021
$2.0MRegulation of T Cell HomeostasisR01AI050631 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CHEN, JIANZHU · 2002 to 2006
$1.6MKoch Institute Faculty Recruitment for an MD/PHD Physician-ScientistP30CA147882 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JACKS, TYLER E. · 2009 to 2010
$1.5MThe role of Mtss1 in Hedgehog-mediated intestinal cancer stem cell functionK08CA198002 · NCI · TUFTS MEDICAL CENTER · PI ROPER, JATIN · 2015 to 2019
$845kRegulation of the Intestinal Stem Cell Niche in AgingR00AG045144 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2014 to 2016
$740kHoward Hughes Medical InstituteNCI NIH HHS C06 CA062520NCI NIH HHS K08 CA198002NCI NIH HHS K99 CA187317NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA147882NCI NIH HHS R01 CA017007NCI NIH HHS R01 CA034992NCI NIH HHS R01 CA120198NCI NIH HHS R01 CA184956NCI NIH HHS R01 CA211184NCI NIH HHS U54 CA163109NIAID NIH HHS R01 AI040146NIAID NIH HHS R01 AI050631NIA NIH HHS K99 AG045144NIA NIH HHS R00 AG045144NIDDK NIH HHS P30 DK043351
Abstract
In vivo interrogation of the function of genes implicated in tumorigenesis is limited by the need to generate and cross germline mutant mice. Here we describe approaches to model colorectal cancer (CRC) and metastasis, which rely on in situ gene editing and orthotopic organoid transplantation in mice without cancer-predisposing mutations. Autochthonous tumor formation is induced by CRISPR-Cas9-based editing of the Apc and Trp53 tumor suppressor genes in colon epithelial cells and by orthotopic transplantation of Apc-edited colon organoids. ApcΔ/Δ;Kras
Indexed as
Disease Models, AnimalAnimalsCarcinogenesisCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsColorectal NeoplasmsFemaleGene EditingGenes, NeoplasmLiver NeoplasmsMaleMiceMice, TransgenicNeoplasm MetastasisOrgan Transplantation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.